Literature DB >> 16984599

Prevalence and risk factors of gallstone disease in an adult population of Taiwan: an epidemiological survey.

Chien-Hua Chen1, Min-Ho Huang, Jee-Chun Yang, Chiu-Kue Nien, Gina Doskey Etheredge, Chi-Chieh Yang, Yung-Hsiang Yeh, Hurng-Sheng Wu, Der-Aur Chou, Sen-Kou Yueh.   

Abstract

BACKGROUND AND AIMS: The aim of this study was to determine the prevalence and risk factors of gallstone disease (GSD) in an adult population of Taiwan through a population-based screening study.
METHODS: A cross-sectional community study in a rural village of Taiwan was conducted in 3333 Chinese adults (aged > or = 18 years) undergoing ultrasonography. A questionnaire on personal history was completed to ascertain whether the removed gallbladder contained stones in all cholecystectomized subjects, the dietary habits (vegetarian/non-vegetarian diet), the history of GSD in the participant's first-degree relatives, the history of gastrointestinal surgery (vagotomy, gastrectomy for peptic ulcer disease, or ileal resection), parity, and use of oral contraceptives. The demographic characteristics and biochemical parameters were recorded.
RESULTS: The overall prevalence of GSD was 5.0% (4.6% in men, 5.4% in women) with no significant sex differences (men/women: odds ratio [OR] 0.71, 95% confidence interval [CI] 0.50-1.01, P = 0.058). Logistic regression analysis showed that increasing age (men: 40-64 years, OR 7.38, 95% CI 2.59-21.01, P < 0.001 and > or = 65 years, OR 14.16, 95% CI 4.84-41.47, P < 0.001; women: 40-64 years, OR 4.08, 95% CI 1.90-8.75, P < 0.001 and > or = 65 years, OR 6.78, 95% CI 2.97-15.46, P < 0.001) and the presence of fatty liver evidenced by ultrasonography (men: OR 2.24, 95% CI 1.32-3.80, P = 0.003; women: OR 2.13, 95% CI 1.33-3.42, P = 0.002) were risk factors for GSD. Additionally, fasting plasma glucose > or = 126 mg/dL (OR 2.11, 95% CI 1.16-3.83, P = 0.014), history of GSD in the first-degree relatives (OR 7.47, 95% CI 2.22-25.12, P = 0.001), and use of oral contraceptives (OR 10.71, 95% CI 3.06-37.49, P < 0.001) were risk factors for GSD in women, but fasting plasma glucose > or = 126 mg/dL was only correlated to GSD without controlling for other confounding factors in men. Other demographic characteristics and biochemical parameters, such as high body mass index (> or = 25 kg/m2), increased parity, hypercholesterolemia, hypertriglyceridemia, hyperuricemia, hepatitis C infection and cirrhosis, did not exhibit any correlation to GSD in logistic regression analysis, although they appeared to be related to GSD in women in univariate analysis.
CONCLUSIONS: Age and fatty liver in both sexes were found to be risk factors for GSD in the study population. The finding of a correlation between fatty liver and GSD is an important addition to the literature concerning the risk factors of GSD. Diabetes mellitus, history of GSD in the first-degree relatives, and use of oral contraceptives were also risk factors for GSD in women.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984599     DOI: 10.1111/j.1440-1746.2006.04381.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  64 in total

1.  SAGES guidelines for the clinical application of laparoscopic biliary tract surgery.

Authors:  D Wayne Overby; Keith N Apelgren; William Richardson; Robert Fanelli
Journal:  Surg Endosc       Date:  2010-08-13       Impact factor: 4.584

2.  Prevalence of cholelithiasis among persons undergoing abdominal ultrasound at the Komfo Anokye Teaching Hospital, Kumasi, Ghana.

Authors:  Adam Gyedu; Kwadwo Adae-Aboagye; Augustina Badu-Peprah
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

3.  Comparison of laparoscopic versus open left-sided hepatectomy for intrahepatic duct stones.

Authors:  Yong Chan Shin; Jin-Young Jang; Mee Joo Kang; Woohyun Jung; Jihoon Chang; Ye Rim Chang; Sun-Whe Kim
Journal:  Surg Endosc       Date:  2015-04-11       Impact factor: 4.584

4.  Cancer risk in patients with cholelithiasis and after cholecystectomy: a nationwide cohort study.

Authors:  Yen-Kung Chen; Jiann-Horng Yeh; Cheng-Li Lin; Chiao-Ling Peng; Fung-Chang Sung; Ing-Ming Hwang; Chia-Hung Kao
Journal:  J Gastroenterol       Date:  2013-06-28       Impact factor: 7.527

5.  Natural Course of Acute Cholecystitis in Patients Treated With Percutaneous Transhepatic Gallbladder Drainage Without Elective Cholecystectomy.

Authors:  Yu-Liang Hung; Sio-Wai Chong; Chi-Tung Cheng; Chien-Hung Liao; Chih-Yuan Fu; Chi-Hsun Hsieh; Ta-Sen Yeh; Chun-Nan Yeh; Yi-Yin Jan; Shang-Yu Wang
Journal:  J Gastrointest Surg       Date:  2019-04-03       Impact factor: 3.452

6.  Risk profile for gallstone disease in southern Indian population: is there anything new?

Authors:  Alexander Palapatti Chandran; Ramya Sivarajan; Vijaya Srinivasan; M Srinivas; V Jayanthi
Journal:  Indian J Gastroenterol       Date:  2014-03-11

7.  Effects of cholecystectomy on recurrent biliary complications after endoscopic treatment of common bile duct stone: a population-based cohort study.

Authors:  Chi-Tung Cheng; Chun-Nan Yeh; Kun-Chun Chiang; Ta-Sen Yeh; Kuan-Fu Chen; Shao-Wei Chen
Journal:  Surg Endosc       Date:  2017-09-15       Impact factor: 4.584

8.  Reproductive factors and risks of biliary tract cancers and stones: a population-based study in Shanghai, China.

Authors:  G Andreotti; L Hou; Y-T Gao; L A Brinton; A Rashid; J Chen; M-C Shen; B-S Wang; T-Q Han; B-H Zhang; L C Sakoda; J F Fraumeni; A W Hsing
Journal:  Br J Cancer       Date:  2010-03-09       Impact factor: 7.640

9.  Metabolic syndrome and gallstone disease.

Authors:  Li-Ying Chen; Qiao-Hua Qiao; Shan-Chun Zhang; Yu-Hao Chen; Guan-Qun Chao; Li-Zheng Fang
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

Review 10.  Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Veeravich Jaruvongvanich; Anawin Sanguankeo; Sikarin Upala
Journal:  Dig Dis Sci       Date:  2016-03-18       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.